146 related articles for article (PubMed ID: 12432257)
1. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.
Marshall JL; Bangalore N; El-Ashry D; Fuxman Y; Johnson M; Norris B; Oberst M; Ness E; Wojtowicz-Praga S; Bhargava P; Rizvi N; Baidas S; Hawkins MJ
Cancer Biol Ther; 2002; 1(4):409-16. PubMed ID: 12432257
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
Jayson GC; Crowther D; Prendiville J; McGown AT; Scheid C; Stern P; Young R; Brenchley P; Chang J; Owens S
Br J Cancer; 1995 Aug; 72(2):461-8. PubMed ID: 7640233
[TBL] [Abstract][Full Text] [Related]
4. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Eilender DS; Hulburd K; Rodriguez DH; Pemberton PA; Pluda JM; Dan MD; Pettit GR; Chen BD; Al-Katib AM
J Clin Oncol; 1998 Jan; 16(1):56-62. PubMed ID: 9440723
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
Philip PA; Rea D; Thavasu P; Carmichael J; Stuart NS; Rockett H; Talbot DC; Ganesan T; Pettit GR; Balkwill F
J Natl Cancer Inst; 1993 Nov; 85(22):1812-8. PubMed ID: 8230261
[TBL] [Abstract][Full Text] [Related]
7. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070
[TBL] [Abstract][Full Text] [Related]
10. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
Prendiville J; Crowther D; Thatcher N; Woll PJ; Fox BW; McGown A; Testa N; Stern P; McDermott R; Potter M
Br J Cancer; 1993 Aug; 68(2):418-24. PubMed ID: 8347500
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.
Varterasian ML; Pemberton PA; Hulburd K; Rodriguez DH; Murgo A; Al-Katib AM
Invest New Drugs; 2001; 19(3):245-7. PubMed ID: 11561682
[TBL] [Abstract][Full Text] [Related]
13. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Zonder JA; Shields AF; Zalupski M; Chaplen R; Heilbrun LK; Arlauskas P; Philip PA
Clin Cancer Res; 2001 Jan; 7(1):38-42. PubMed ID: 11205915
[TBL] [Abstract][Full Text] [Related]
15. Delta-protein kinase C phosphorylation parallels inhibition of nerve growth factor-induced differentiation independent of changes in Trk A and MAP kinase signalling in PC12 cells.
Wooten MW; Seibenhener ML; Heikkila JE; Mischak H
Cell Signal; 1998 Apr; 10(4):265-76. PubMed ID: 9617484
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study.
Tozer RG; Burdette-Radoux S; Berlanger K; Davis ML; Lohmann RC; Rusthoven JR; Wainman N; Zee B; Seymour L;
Invest New Drugs; 2002 Nov; 20(4):407-12. PubMed ID: 12448658
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of bryostatin-1 in metastatic melanoma.
Bedikian AY; Plager C; Stewart JR; O'Brian CA; Herdman SK; Ross M; Papadopoulos N; Eton O; Ellerhorst J; Smith T
Melanoma Res; 2001 Apr; 11(2):183-8. PubMed ID: 11333129
[TBL] [Abstract][Full Text] [Related]
18. A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.
Madhusudan S; Protheroe A; Propper D; Han C; Corrie P; Earl H; Hancock B; Vasey P; Turner A; Balkwill F; Hoare S; Harris AL
Br J Cancer; 2003 Oct; 89(8):1418-22. PubMed ID: 14562010
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Pfister DG; McCaffrey J; Zahalsky AJ; Schwartz GK; Lis E; Gerald W; Huvos A; Shah J; Kraus D; Shaha A; Singh B; Wolden S; Zelefsky M; Palgi I
Invest New Drugs; 2002 Feb; 20(1):123-7. PubMed ID: 12003188
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]